Coagulation state in patients with Crohn's disease: The effect of infliximab therapy

European Journal of Gastroenterology and Hepatology

Volumn 26, Issue 9, 2014, Pages 955-963

  Wang, Xiaobing ^a,b   Wang, Ge ^a,b   Wang, Jinghui ^a,b   Liu, Shi ^a,b   Zhou, Rui ^a,b   Chen, Liping ^a,b   Wu, Ting ^a,b   Huang, Meifang ^a   Li, Jin ^a   Song, Lu ^a,b   Xia, Bing ^a,b  

^a ZHONGNAN HOSPITAL OF WUHAN UNIVERSITY   (China)

^b Hubei Cancer Clinical Study Center   (China)

Author keywords

coagulation state; Crohn's disease; infliximab therapy

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; D DIMER; FIBRINOGEN; INFLIXIMAB; FIBRIN DEGRADATION PRODUCT; FIBRIN FRAGMENT D; GASTROINTESTINAL AGENT; MONOCLONAL ANTIBODY;

ADULT; ARTICLE; BLOOD ANALYSIS; BLOOD CLOTTING; CASE STUDY; CONCENTRATION (PARAMETERS); CONTROL; CONTROLLED STUDY; CROHN DISEASE; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HEMATOLOGICAL PARAMETERS; HUMAN; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; RETROSPECTIVE STUDY; THROMBIN TIME; THROMBOCYTE COUNT; THROMBOCYTE VOLUME; BLOOD; BLOOD CLOTTING TEST; CASE CONTROL STUDY; DRUG EFFECTS; DRUG SCREENING; METABOLISM; MIDDLE AGED; PATHOLOGY; PROCEDURES; YOUNG ADULT;

ADULT; ANTIBODIES, MONOCLONAL; BLOOD COAGULATION; BLOOD COAGULATION TESTS; CASE-CONTROL STUDIES; CROHN DISEASE; DRUG EVALUATION; FEMALE; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; GASTROINTESTINAL AGENTS; HUMANS; MALE; MEAN PLATELET VOLUME; MIDDLE AGED; PLATELET COUNT; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84905364993     PISSN: 0954691X     EISSN: 14735687     Source Type: Journal    
DOI: 10.1097/MEG.0000000000000133     Document Type: Article

References (50)

1. Xavier RJ, Podolsky DK. Unravelling the pathogenesis of inflammatory bowel disease. Nature 2007; 448:427-434.
2. Maloy KJ, Powrie F. Intestinal homeostasis and its breakdown in inflammatory bowel disease. Nature 2011; 474:298-306.
3. Gionchetti P, Calabrese C, Tambasco R, Brugnera R, Straforini G, Liguori G, et al. Role of conventional therapies in the era of biological treatment in Crohn's disease. World J Gastroenterol 2011; 17:1797-1806.
4. Burger D, Travis S. Conventional medical management of inflammatory bowel disease. Gastroenterology 2011; 140:1827-1837.e2.
5. Ebert EC. Infliximab and the TNF-alpha system. Am J Physiol Gastrointest Liver Physiol 2009; 296:G612-G620.
6. Ruemmele FM, Lachaux A, Cézard JP, Morali A, Maurage C, Giniès JL, et al. Groupe Francophone d'Hépatologie, Gastroentérologie et Nutrition Pédiatrique. Efficacy of infliximab in pediatric Crohn's disease: a randomized multicenter open-label trial comparing scheduled to on demand maintenance therapy. Inflamm Bowel Dis 2009; 15:388-394.
7. Colombel JF, Sandborn WJ, Reinisch W, Mantzaris GJ, Kornbluth A, Rachmilewitz D, et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 2010; 362:1383-1395.
8. Rutgeerts P, D'Haens G, Targan S, Vasiliauskas E, Hanauer SB, Present DH, et al. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Gastroenterology 1999; 117:761-769.
9. Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, et al. ACCENT I Study Group. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002; 359:1541-1549.
10. Sands BE, Anderson FH, Bernstein CN, Chey WY, Feagan BG, Fedorak RN, et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med 2004; 350:876-885.
11. Lémann M, Mary JY, Duclos B, Veyrac M, Dupas JL, Delchier JC, et al. Groupe d'Etude Therapeutique des Affections Inflammatoires du Tube Digestif (GETAID). Infliximab plus azathioprine for steroid-dependent Crohn's disease patients: a randomized placebo-controlled trial. Gastroenterology 2006; 130:1054-1061.
12. Zabana Y, Domènech E, Mañosa M, Garcia-Planella E, Bernal I, Cabré E, Gassull MA. Infliximab safety profile and long-term applicability in inflammatory bowel disease: 9-year experience in clinical practice. Aliment Pharmacol Ther 2010; 31:553-560.
13. Ljung T, Karlén P, Schmidt D, Hellström PM, Lapidus A, Janczewska I, et al. Infliximab in inflammatory bowel disease: clinical outcome in a population based cohort from Stockholm County. Gut 2004; 53:849-853.
14. Puli SR, Benage DD. Retinal vein thrombosis after infliximab (Remicade) treatment for Crohn's disease. Am J Gastroenterol 2003; 98:939-940.
15. Veerappan SG, Kennedy M, O'Morain CA, Ryan BM. Retinal vein thrombosis following infliximab treatment for severe left-sided ulcerative colitis. Eur J Gastroenterol Hepatol 2008; 20:588-589.
16. Ryan BM, Romberg M, Wolters F, Stockbrugger RW. Extensive forearm deep venous thrombosis following a severe infliximab infusion reaction. Eur J Gastroenterol Hepatol 2004; 16:941-942.
17. Grange L, Nissen MJ, Garambois K, Dumolard A, Duc C, Gaudin P, Juvin R. Infliximab-induced cerebral thrombophlebitis. Rheumatology (Oxford) 2005; 44:260-261.
18. Kumar DR, Hanlin E, Glurich I, Mazza JJ, Yale SH. Virchow's contribution to the understanding of thrombosis and cellular biology. Clin Med Res 2010; 8:168-172.
19. Danese S, Papa A, Saibeni S, Repici A, Malesci A, Vecchi M. Inflammation and coagulation in inflammatory bowel disease: the clot thickens. Am J Gastroenterol 2007; 102:174-186.
20. Yoshida H, Granger DN. Inflammatory bowel disease: a paradigm for the link between coagulation and inflammation. Inflamm Bowel Dis 2009; 15:1245-1255.
21. Satsangi J, Silverberg MS, Vermeire S, Colombel JF. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut 2006; 55:749-753.
22. Best WR, Becktel JM, Singleton JW, Kern F Jr. Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology 1976; 70:439-444.
23. Chiarantini E, Valanzano R, Liotta AA, Cellai AP, Fedi S, Ilari I, et al. Hemostatic abnormalities in inflammatory bowel disease. Thromb Res 1996; 82:137-146.
24. Palareti G, Cosmi B, Legnani C, Tosetto A, Brusi C, Lorio A, et al. D-dimer testing to determine the duration of anticoagulation therapy. N Engl J Med 2006; 355:1780-1789.
25. Kyrle PA, Eichinger S. New diagnostic strategies for pulmonary embolism. Lancet 2008; 371:1312-1315.
26. Kyrle PA, Rosendaal FR, Eichinger S. Risk assessment for recurrent venous thrombosis. Lancet 2010; 376:2032-2039.
27. Bates SM. D-dimer assays in diagnosis and management of thrombotic and bleeding disorders. Semin Thromb Hemost 2012; 38:673-682.
28. Wada H, Kobayashi T, Abe Y, Hatada T, Yamada N, Sudo A, et al. Elevated levels of soluble fibrin or D-dimer indicate high risk of thrombosis. J Thromb Haemost 2006; 4:1253-1258.
29. Bonnin P, Coelho J, Pocard M, Levy BI, Marteau P. Anti-TNF? therapy early improves hemodynamics in local intestinal and extraintestinal circulations in active Crohn's disease. J Crohns Colitis 2013; 7:451-459.
30. Krem MM, Di Cera E. Evolution of enzyme cascades from embryonic development to blood coagulation. Trends Biochem Sci 2002; 27:67-74.
31. Loof TG, Schmidt O, Herwald H, Theopold U. Coagulation systems of invertebrates and vertebrates and their roles in innate immunity: the same side of two coins? J Innate Immun 2011; 3:34-40.
32. Voudoukis E, Karmiris K, Oustamanolakis P, Theodoropoulou A, Sfiridaki A, Paspatis GA, Koutroubakis IE. Association between thrombocytosis and iron deficiency anemia in inflammatory bowel disease. Eur J Gastroenterol Hepatol 2013; 25:1212-1216.
33. Voudoukis E, Karmiris K, Koutroubakis IE. Multipotent role of platelets in inflammatory bowel diseases: a clinical approach. World J Gastroenterol 2014; 20:3180-3190.
34. Kadikoylu G, Yavasoglu I, Bolaman Z, Senturk T. Platelet parameters in women with iron deficiency anemia. J Natl Med Assoc 2006; 98:398-402.
35. Kuku I, Kaya E, Yologlu S, Gokdeniz R, Baydin A. Platelet counts in adults with iron deficiency anemia. Platelets 2009; 20:401-405.
36. Kapsoritakis AN, Koukourakis MI, Sfiridaki A, Potamianos SP, Kosmadaki MG, Koutroubakis IE, Kouroumalis EA. Mean platelet volume: a useful marker of inflammatory bowel disease activity. Am J Gastroenterol 2001; 96:776-781.
37. Smyth SS, McEver RP, Weyrich AS, Morrell CN, Hoffman MR, Arepally GM, et al. Platelet functions beyond hemostasis. J Thromb Haemost 2009; 7:1759-1766.
38. Miehsler W, Reinisch W, Valic E, Osterode W, Tillinger W, Feichtenschlager T, et al. Is inflammatory bowel disease an independent and disease specific risk factor for thromboembolism? Gut 2004; 53:542-548.
39. Papay P, Miehsler W, Tilg H, PetritschW, ReinischW, Mayer A, et al. Clinical presentation of venous thromboembolism in inflammatory bowel disease. J Crohns Colitis 2013; 7:723-729.
40. Novacek G, Weltermann A, Sobala A, Tilg H, Petritsch W, Renisch W, et al. Inflammatory bowel disease is a risk factor for recurrent venous thromboembolism. Gastroenterology 2010; 139:779-787, 787.e1.
41. Kappelman MD, Horvath-Puho E, Sandler RS, Rubin DT, Ullman TA, Pedersen L, et al. Thromboembolic risk among Danish children and adults with inflammatory bowel diseases: a population-based nationwide study. Gut 2011; 60:937-943.
42. Bernstein CN, Blanchard JF, Houston DS, Wajda A. The incidence of deep venous thrombosis and pulmonary embolism among patients with inflammatory bowel disease: a population-based cohort study. Thromb Haemost 2001; 85:430-434.
43. Nguyen GC, Sam J. Rising prevalence of venous thromboembolism and its impact on mortality among hospitalized inflammatory bowel disease patients. Am J Gastroenterol 2008; 103:2272-2280.
44. Koutroubakis IE. Venous thromboembolism in hospitalized inflammatory bowel disease patients: the magnitude of the problem is staggering. Am J Gastroenterol 2008; 103:2281-2283.
45. Tan VP, Chung A, Yan BP, Gibson PR. Venous and arterial disease in inflammatory bowel disease. J Gastroenterol Hepatol 2013; 28:1095-1113.
46. Grainge MJ, West J, Card TR. Venous thromboembolism during active disease and remission in inflammatory bowel disease: a cohort study. Lancet 2010; 375:657-663.
47. Sridhar AR, Parasa S, Navaneethan U, Crowell MD, Olden K. Comprehensive study of cardiovascular morbidity in hospitalized inflammatory bowel disease patients. J Crohns Colitis 2011; 5:287-294.
48. Barclay AR, Keightley JM, Horrocks I, Garrick V, McGrogan P, Russell RK. Cerebral thromboembolic events in pediatric patients with inflammatory bowel disease. Inflamm Bowel Dis 2010; 16:677-683.
49. Murthy SK, Nguyen GC. Venous thromboembolism in inflammatory bowel disease: an epidemiological review. Am J Gastroenterol 2011; 106:713-718.
50. Solem CA, Loftus EV, Tremaine WJ, Sandborn WJ. Venous thromboembolism in inflammatory bowel disease. Am J Gastroenterol 2004; 99:97-101.